QYQiuxia Yang

Qiuxia Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiuxia Yang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Jianyao Zhou

    Department of Radiology, Affiliated Dongguan Hospital Southern Medical University Dongguan China

    4 shared publications
  • Rong Zhang

    Department of Radiology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China

    4 shared publications
  • Lizhi Liu

    Department of Radiology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China

    3 shared publications
  • Yize Mao

    Department of Pancreatobiliary Surgery State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China

    3 shared publications
  • Jiahui Xu

    Department of Medical Imaging, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China

    2 shared publications
  • Qiulin Liu

    Department of Radiology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China

    2 shared publications

Latest Publications

  • Open Access

    Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy

    by Jun Cheng, Yize Mao, Shuxiang Huang, Xiaotong Tan, Xiaoping Yi, Xiaoying Du, Qiulin Liu, Jianyao Zhou, Rong Huang, Weijie Chen, et al.

    Advanced pancreatic ductal adenocarcinoma (PDAC) often progresses rapidly during chemotherapy despite initial assessments of stable disease or partial response by Response Evaluation Criteria in Solid Tumors (RECIST 1.1), underscoring the limitations of the current methods for predicting short‐term progressive disease (PD). To address this, the study developed a spatiotemporal deep learning framework that integrates convolutional and long short‐term memory (LSTM) neural networks to dynamically predict PD at the next follow‐up visit using serial computed tomography (CT) scans and baseline clinical variables. The model was trained on a retrospective cohort of 243 patients (415 predicted events, defined as temporal sequences for the next follow‐up PD prediction) and evaluated across internal, external, and prospective cohorts. The model achieved area under the curve (AUC) values of 0.77, 0.76, and 0.74, respectively. Performance remained robust across chemotherapy regimens (AG or Gemcitabine‐based, FOLFIRINOX, and SOXIRI; AUC 0.68–0.79), PD subtypes (target lesion growth vs. new metastases; AUC 0.72 vs. 0.77), and baseline disease stages (locally advanced vs. metastatic; AUC 0.85 vs. 0.71). This framework enables the noninvasive, real‐time prediction of imminent PD in advanced PDAC, facilitating timely treatment modification. Its validated generalizability and reliance on routine clinical data underscore its potential for seamless integration into chemotherapy management.

  • Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer

    by Sen Lei, Yize Mao, Tao Qin, Jianyao Zhou, Zhijun Mai, Jiahui Xu, Rong Zhang, Qiuxia Yang


  • Open Access

    Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel

    by Qiuxia Yang, Yize Mao, Yulong Han, Kailai Li, Wanming Hu, Jianyao Zhou, Xuejun Gong, Shuxiang Huang, Rong Zhang, Lizhi Liu, et al.

    Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis. Chemotherapy remains the mainstay for unresectable cases, yet regimens like AG (gemcitabine/nab-paclitaxel) exhibit heterogeneous efficacy. Tumor fibrosis has emerged as a potential predictor of treatment response but lacks validated noninvasive assessment methods. To address this, in this multicenter study, tumor fibrosis was quantified in 361 patients with resectable PDAC from SYSUCC, XYCSU, and TCGA cohorts using deep learning-based tissue segmentation on hematoxylin and eosin-stained whole-slide images. Fibrosis was defined as stromal proportion, and its association with overall survival (OS) was evaluated. Transcriptomic profiling was performed in 51 XYCSU cases to validate the biological relevance of fibrosis quantification. A radiomics model (RM) was then developed using preoperative contrast-enhanced computed tomography (CT) scans from SYSUCC to predict fibrosis and externally validated in XYCSU. Clinical utility was assessed in an independent cohort of 295 unresectable PDAC patients treated with AG, FOLFIRINOX, or SOXIRI. High fibrosis correlated with prolonged OS across resectable cohorts (all P < 0.05). Transcriptomic analysis revealed enrichment of fibrosis-related pathways in high-fibrosis tumors. The RM achieved an area under the curve of 0.718 (95% confidence interval: 0.627 to 0.823) in the external test set. Among patients receiving AG, those with CT-predicted high fibrosis had significantly longer progression-free survival (median: 6.23 versus 4.70 months, P = 0.037) and OS (13.37 versus 7.73 months, P = 0.002). No significant survival benefit was observed for high-fibrosis patients receiving FOLFIRINOX or SOXIRI. CT-based fibrosis quantification offers a robust, noninvasive biomarker for predicting AG efficacy in unresectable PDAC.


  • Open Access

    Feasible CT features to distinguish incidental rib enhancement from sclerotic metastasis in patients with malignancies

    by Qiuxia Yang, Jiahui Xu, Jianyao Zhou, Qiulin Liu, Zhijun Mai, Hui Xie, Xiaohua Ban, Lizhi Liu, Rong Zhang

    Objective: To investigate the CT features of incidental rib enhancement (RE) and to summarize the CT characteristics for distinguishing the RE from sclerotic metastasis (SM) in patients with malignancies. Material and methods: This retrospective observational study enrolled 79 patients with RE (involved 133 ribs) during October 2014 and December 2021. Another 53 patients with SM (160 SM) in the same period were selected randomly for comparison. The location, enhancement patterns of RE were reviewed. The CT values of RE regions and SM were measured and statistically analyzed. Results: Most REs (70 patients, 88.6%) were in the 1st to 6th ribs. 50 patients had solitary RE and 29 with multiple REs in a regional distribution. All the REs were closely connected to the intercostal venous plexus (ICVP) ipsilateral to the injection site. No visible abnormalities on unenhanced scans were detected in all REs. One hundred and twenty REs (90.2%) had nodular/patchy enhancement. The CT value of RE regions in the venous phase was lower than that in the arterial phase (589.8 ± 344.2 HU versus 1188.5 ± 325.3 HU, p < 0.001). During the venous phase, most REs (125, 94.0%) shrank or disappeared. SM appeared similar on both contrast-enhanced and unenhanced scans in terms of shape and CT values. Conclusion: The RE demonstrated characteristic CT features. The manifestations of nodular/patchy enhancement in the arterial phase, decreased density and shrinkage or disappearance during the venous phase, and no abnormality on unenhanced scans, as well as a close connection with the ICVP, may help differentiate RE from SM.

  • Association of body composition with survival and inflammatory responses in patients with non-metastatic nasopharyngeal cancer

    by Wen-Zhuo He, Chang Jiang, Li-Li Liu, Chen-Xi Yin, Yu-Ming Rong, Wan-Ming Hu, Lin Yang, Lei Wang, Ya-Nan Jin, Xiao-Ping Lin, et al.


  • Spectral CT with monochromatic imaging and metal artifacts reduction software for artifacts reduction of 125I radioactive seeds in liver brachytherapy

    by Qiuxia Yang, Sheng Peng, Jing Wu, Xiaohua Ban, Mingyan He, Chuanmiao Xie, Rong Zhang

    To investigate the optimal monochromatic energy for artifacts reduction from 125I seeds as well as image improvement in the vicinity of seeds on monochromatic images with and without metal artifacts reduction software (MARS) and to compare this with traditional 120-kVp images, so as to evaluate the application value of gemstone spectral imaging for reducing artifacts from 125I seeds in liver brachytherapy.